tradingkey.logo

BUZZ-J.P. Morgan upgrades bluebird bio to 'neutral'

ReutersFeb 24, 2025 11:21 AM

J.P. Morgan upgrades gene therapy maker bluebird bio BLUE.O to "neutral" from "underweight" rating, citing co's announcement that it would be taken private

Brokerage expects co's privatization to take place within 1H25

BLUE says it will be taken private by Carlyle CG.O and SK Capital Partners

1 of 8 brokerages rate BLUE stock "buy", 7 "hold"; their median PT is $10 - LSEG data

As of last close, stock down ~51.1% YTD

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI